Drug Trial Radar · NCT07431060
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 13, 2026
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- West China Second University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 24, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder in children, caused by excessive proliferation and accumulation of Langerhans cells (a type of immune cell) in various body tissues. The annual incidence is about 2.6-8.9 cases per million children.Clinical presentation varies widely. Mild (low-risk) cases may resolve spontaneously or cause minimal issues with excellent outcomes. Severe multisystem LCH involves multiple organs, particularly high-risk sites such as liver, spleen, or bone marrow, leading to poorer prognosis and potential life-threatening complications without appropriate treatment.Standard first-line therapy for many children is prednisone (a corticosteroid) plus vinblastine (chemotherapy). Trials like LCH-III show near-100% survival in low-risk disease, but long-term survival drops to \~80% in high-risk cases. Reactivation occurs in \~37% of low-risk patients post-treatment, and \~50% of children eventually develop resistance, resulting in progression or relapse. Treatment failure heightens risks of long-term sequelae, including growth retardation, endocrine dysfunction, and neurological damage, severely impacting quality of life. More than half of LCH cases harbor the BRAF V600E mutation, activating the MAPK pathway abnormally. This has driven development of targeted MAPK inhibitors (e.g., vemurafenib, dabrafenib, trametinib), which demonstrate strong efficacy and acceptable safety (mainly manageable skin rash) in relapsed/refractory pediatric cases, with no reported secondary malignancies to date. These agents provide rapid symptom relief and durable control, though monotherapy often fails to eradicate abnormal cells in multisystem disease, leading to relapse after discontinuation. No MAPK inhibitors were previously approved specifically for LCH. In 2025, luvometinib (developed by Fosun Pharma, China; a selective MEK1/2 inhibitor) received approval in China for adult LCH and histiocytic neoplasms. Adult studies showed \~83% objective response rate and \~74% progression-free at ≥12 months, with mostly mild side effects (skin issues, hypertriglyceridemia) and no discontinuations due to serious toxicity. Laboratory evidence indicates MAPK overactivation confers apoptosis resistance to LCH cells; combining MAPK inhibitors with chemotherapy may enhance cell killing and leverage chemotherapy-induced immune microenvironment changes for better clearance. Small studies and real-world data in refractory LCH support this: combination regimens yielded low relapse rates (especially with prolonged therapy), 100% responses in some pediatric cohorts with sustained remission and no added severe toxicity, and notably lower relapse (20% vs 75% with inhibitor alone) in our center's early experience with LCH-III backbone plus MAPK inhibitor. This multicenter randomized trial will enroll children with multisystem LCH, assigning them to modified standard LCH-III chemotherapy alone or the same regimen combined with luvometinib, to evaluate whether adding this targeted agent improves outcomes.
Conditions
- Langerhans Cell Histiocytosis (LCH)
Interventions
PrednisoneDrug
Corticosteroid administered orally as part of the modified LCH-III regimen
VincristineDrug
Intravenous vinca alkaloid chemotherapy agent used in the modified LCH-III regimen
MercaptopurineDrug
Oral purine analog antimetabolite used in the maintenance phase of therapy for multisystem LCH
LuvometinibDrug
Oral selective MEK1/2 inhibitor added to the experimental arm. Administered daily in combination with modified LCH-III chemotherapy for multisystem Langerhans cell histiocytosis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-Free survival rateTime frame: From Day 1 until the date of first event or last follow-up, assessed up to 2 years.
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
West China Second Hospital, Sichuan University
Chengdu, China · Recruiting
Affiliated Hospital of Guizhou Medical University
Guiyang, China · Recruiting
Anhui Provincial Children's Hospital
Hefei, China · Recruiting
The Second Affiliated Hospital of Anhui Medical University
Hefei, China · Recruiting
Jiangxi Provincial Children's Hospital
Jiangxi, China · Recruiting
Kunming Children's Hospital
Kunming, China · Recruiting
The Second Affiliated Hospital of Guangxi Medical University
Nanning, China · Recruiting
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, China · Recruiting
Xi'an Children's Hospital
Xi'an, China · Recruiting
Xi'an Northwest Women's and Children's Hospital
Xi'an, China · Recruiting
Zunyi Medical University Affiliated Hospital, Guizhou Provincial Children's Hospital
Zunyi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.